Entropy Technologies’s CorMedix CRMD Stock Holding History

Entropy Technologies’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,297	Closed	-$139K	–	867
2025 Q2	$139K	Buy	+11,297	New	+$125K	0.01%	731

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Entropy Technologies's CRMD Position: Q3 2025 in Review

Entropy Technologies sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 11,297 shares — an estimated $139K sold.

Entropy Technologies first reported a position in CRMD in Q2 2025 and held it in 1 quarter. The position peaked at $139K in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

Entropy Technologies reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
Entropy Technologies sold 11,297 CorMedix shares in Q3 2025, an estimated $139K.
Entropy Technologies first reported a position in CorMedix in Q2 2025 and held it in 1 quarter.
Entropy Technologies's CorMedix position peaked at $139K in Q2 2025.
190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on Entropy Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.